-

Bausch + Lomb to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders will participate in a fireside chat with investors at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 8, 2024, at 11:15 a.m. PT (2:15 p.m. ET). Other company executives, including Chief Financial Officer Sam Eldessouky and Global Pharmaceuticals and International Consumer President Andrew Stewart, will also participate in the conference.

A live webcast and audio archive of the event will be available on the Investor Relations page of the Bausch + Lomb website: https://ir.bausch.com/investors/events-presentations.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

© 2024 Bausch + Lomb.

Contacts

Media:
T.J. Crawford
tj.crawford@bausch.com
(908) 705-2851

Investor:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)

Bausch + Lomb Corporation

NYSE:BLCO

Release Versions

Contacts

Media:
T.J. Crawford
tj.crawford@bausch.com
(908) 705-2851

Investor:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)

More News From Bausch + Lomb Corporation

Bausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced European CE Mark approval of SeeLyra, the company’s next generation femtosecond laser. One of the most compact femtosecond platforms available, SeeLyra provides surgeons precision and control when performing laser preparation for premium cataract, LASIK flap and corneal therapeutic surgeries while simultaneously...

Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses (IOLs). The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal lenses delivered both good distance and functional intermediate vision, thus meeting...

Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap around dry eye and its association with perimenopause and menopause. The survey found that dry eye remains one of the least recognized symptoms experienced during these stages of life. According to the survey, only 14% of peri-, menopausal and p...
Back to Newsroom